{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:29:09Z","timestamp":1793730549921,"version":"4.6.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100019721","name":"Roche Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019721","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s40120-023-00571-9","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T05:01:48Z","timestamp":1704430908000},"page":"233-249","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Design and Validation of a Clinical Outcome Measure for Adolescents and Adult Patients with Spinal Muscular Atrophy: SMA Life Study Protocol"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7517-6540","authenticated-orcid":false,"given":"Pablo","family":"Rebollo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sof\u00eda","family":"Garc\u00eda-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Povedano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda G.","family":"Cattinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Mart\u00ednez-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngeles","family":"Terrancle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosana","family":"Cabello-Moruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3043-7938","authenticated-orcid":false,"given":"Juan F.","family":"V\u00e1zquez-Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,5]]},"reference":[{"issue":"2","key":"571_CR1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s13311-014-0314-x","volume":"12","author":"MA Farrar","year":"2015","unstructured":"Farrar MA, Kiernan MC. The genetics of spinal muscular atrophy: progress and challenges. Neurotherapeutics. 2015;12(2):290\u2013302.","journal-title":"Neurotherapeutics"},{"issue":"4","key":"571_CR2","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","volume":"33","author":"SJ Kolb","year":"2015","unstructured":"Kolb SJ, Kissel JT. Spinal muscular atrophy. Neurol Clin. 2015;33(4):831\u201346.","journal-title":"Neurol Clin"},{"issue":"6","key":"571_CR3","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.nmd.2023.03.011","volume":"33","author":"MC Walter","year":"2023","unstructured":"Walter MC, Lafor\u00eat P, van der Pol WL, Pegoraro E. 254th ENMC international workshop. Formation of a European network to initiate a European data collection, along with development and sharing of treatment guidelines for adult SMA patients. Virtual meeting 28\u201330 January 2022. Neuromuscular Disord NMD. 2023;33(6):511\u201322.","journal-title":"Neuromuscular Disord NMD."},{"issue":"7","key":"571_CR4","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.3390\/jcm9072222","volume":"9","author":"S Messina","year":"2020","unstructured":"Messina S, Sframeli M. New treatments in spinal muscular atrophy: positive results and new challenges. J Clin Med. 2020;9(7):2222.","journal-title":"J Clin Med"},{"issue":"7","key":"571_CR5","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, et al. Nusinersen versus Sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378(7):625\u201335.","journal-title":"N Engl J Med"},{"issue":"18","key":"571_CR6","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"11","key":"571_CR7","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1111\/ene.15501","volume":"29","author":"JF V\u00e1zquez-Costa","year":"2022","unstructured":"V\u00e1zquez-Costa JF, Povedano M, Nascimiento-Osorio AE, Moreno Escribano A, Kapetanovic Garcia S, Dominguez R, et al. Nusinersen in adult patients with 5q spinal muscular atrophy: a multicenter observational cohorts\u2019 study. Eur J Neurol. 2022;29(11):3337\u201346.","journal-title":"Eur J Neurol"},{"issue":"5","key":"571_CR8","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/mus.27804","volume":"67","author":"NC \u00d1ungo Garz\u00f3n","year":"2023","unstructured":"\u00d1ungo Garz\u00f3n NC, Pitarch Castellano I, Sevilla T, V\u00e1zquez-Costa JF. Risdiplam in non-sitter patients aged 16 years and older with 5q spinal muscular atrophy. Muscle Nerve. 2023;67(5):407\u201311.","journal-title":"Muscle Nerve"},{"issue":"2","key":"571_CR9","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/ene.14567","volume":"28","author":"VA Sansone","year":"2021","unstructured":"Sansone VA, Coratti G, Pera MC, Pane M, Messina S, Salmin F, et al. Sometimes they come back: new and old spinal muscular atrophy adults in the era of nusinersen. Eur J Neurol. 2021;28(2):602\u20138.","journal-title":"Eur J Neurol"},{"issue":"4","key":"571_CR10","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3233\/JND-200534","volume":"7","author":"VA Sansone","year":"2020","unstructured":"Sansone VA, Walter MC, Attarian S, Delstanche S, Mercuri E, Lochm\u00fcller H, et al. Measuring outcomes in adults with spinal muscular atrophy - challenges and future directions\u2014meeting report. J Neuromuscular Dis. 2020;7(4):523\u201334.","journal-title":"J Neuromuscular Dis"},{"key":"571_CR11","doi-asserted-by":"crossref","unstructured":"V\u00e1zquez-Costa JF, Povedano M, Nascimiento-Osorio AE, Moreno Escribano A, Kapetanovic Garcia S, Dominguez R, Exposito JM, Gonz\u00e1lez L, Marco C, Medina Castillo J, Muelas N, Natera de Benito D, \u00d1ungo Garz\u00f3n NC,\nPitarch Castellano I, Sevilla T, Herv\u00e1s D. Validation of motor and functional scales for the evaluation of adult patients with 5q spinal muscular atrophy. Eur J Neurol. 2022;29(12):3666\u201375.","DOI":"10.1111\/ene.15542"},{"issue":"6","key":"571_CR12","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1111\/ene.14780","volume":"28","author":"JF V\u00e1zquez-Costa","year":"2021","unstructured":"V\u00e1zquez-Costa JF, Herv\u00e1s D. Minimal detectable change and minimal clinically important difference in spinal muscular atrophy patients. Eur J Neurol. 2021;28(6):e40\u20131.","journal-title":"Eur J Neurol"},{"issue":"4","key":"571_CR13","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3233\/JND-200611","volume":"8","author":"MC Walter","year":"2021","unstructured":"Walter MC, Chiriboga C, Duong T, Goemans N, Mayhew A, Ouillade L, et al. Improving care and empowering adults living with SMA: a call to action in the new treatment era. J Neuromuscular Dis. 2021;8(4):543\u201351.","journal-title":"J Neuromuscular Dis"},{"issue":"5","key":"571_CR14","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/mus.27519","volume":"65","author":"N Rad","year":"2022","unstructured":"Rad N, Cai H, Weiss MD. Management of spinal muscular atrophy in the adult population. Muscle Nerve. 2022;65(5):498\u2013507.","journal-title":"Muscle Nerve"},{"issue":"7","key":"571_CR15","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.nmd.2015.04.009","volume":"25","author":"R Finkel","year":"2015","unstructured":"Finkel R, Bertini E, Muntoni F, Mercuri E. 209th ENMC International Workshop: outcome measures and clinical trial readiness in spinal muscular atrophy 7\u20139 November 2014, Heemskerk The Netherlands. Neuromuscular Disord NMD. 2015;25(7):593\u2013602.","journal-title":"Neuromuscular Disord NMD"},{"issue":"3","key":"571_CR16","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.nrl.2021.07.008","volume":"37","author":"I Pitarch Castellano","year":"2022","unstructured":"Pitarch Castellano I, Cabrera-Serrano M, Calvo Medina R, Cattinari MG, Espinosa Garc\u00eda S, Fern\u00e1ndez-Ramos JA, et al. Delphi consensus on recommendations for the treatment of spinal muscular atrophy in Spain (RET-AME consensus). Neurologia. 2022;37(3):216\u201328.","journal-title":"Neurologia"},{"issue":"4","key":"571_CR17","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3233\/JND-200617","volume":"8","author":"J Slayter","year":"2021","unstructured":"Slayter J, Hodgkinson V, Lounsberry J, Brais B, Chapman K, Genge A, et al. A Canadian adult spinal muscular atrophy outcome measures toolkit: results of a national consensus using a modified Delphi method. J Neuromuscular Dis. 2021;8(4):579\u201388.","journal-title":"J Neuromuscular Dis"},{"issue":"5","key":"571_CR18","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1007\/s00415-020-10332-5","volume":"268","author":"G Querin","year":"2021","unstructured":"Querin G, Lenglet T, Debs R, Stojkovic T, Behin A, Salachas F, et al. Development of new outcome measures for adult SMA type III and IV: a multimodal longitudinal study. J Neurol. 2021;268(5):1792\u2013802.","journal-title":"J Neurol"},{"issue":"4","key":"571_CR19","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1001\/jamaneurol.2019.4490","volume":"77","author":"CN Fournier","year":"2020","unstructured":"Fournier CN, Bedlack R, Quinn C, Russell J, Beckwith D, Kaminski KH, et al. Development and validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS). JAMA Neurol. 2020;77(4):480\u20138.","journal-title":"JAMA Neurol"},{"issue":"5","key":"571_CR20","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1136\/jnnp-2021-328194","volume":"93","author":"RPA van Eijk","year":"2022","unstructured":"van Eijk RPA, van den Berg LH, Lu Y. Composite endpoint for ALS clinical trials based on patient preference: patient-ranked order of function (PROOF). J Neurol Neurosurg Psychiatry. 2022;93(5):539\u201346.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"571_CR21","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.nmd.2005.03.004","volume":"15","author":"C B\u00e9rard","year":"2005","unstructured":"B\u00e9rard C, Payan C, Hodgkinson I, Fermanian J. A motor function measure for neuromuscular diseases. Construction and validation study. Neuromuscular Disord NMD. 2005;15(7):463\u201370.","journal-title":"Neuromuscular Disord NMD."},{"issue":"12","key":"571_CR22","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1177\/0883073811420294","volume":"26","author":"AM Glanzman","year":"2011","unstructured":"Glanzman AM, O\u2019Hagen JM, McDermott MP, Martens WB, Flickinger J, Riley S, et al. Validation of the expanded hammersmith functional motor scale in spinal muscular atrophy type II and III. J Child Neurol. 2011;26(12):1499\u2013507.","journal-title":"J Child Neurol"},{"issue":"6","key":"571_CR23","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/mus.25430","volume":"55","author":"ES Mazzone","year":"2017","unstructured":"Mazzone ES, Mayhew A, Montes J, Ramsey D, Fanelli L, Young SD, et al. Revised upper limb module for spinal muscular atrophy: development of a new module. Muscle Nerve. 2017;55(6):869\u201374.","journal-title":"Muscle Nerve"},{"key":"571_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.120059","volume":"432","author":"D Trundell","year":"2022","unstructured":"Trundell D, Skalicky A, Staunton H, Hareendran A, Le Scouiller S, Barrett L, et al. Development of the SMA independence scale-upper limb module (SMAIS-ULM): a novel scale for individuals with Type 2 and non-ambulant Type 3 SMA. J Neurol Sci. 2022;432: 120059.","journal-title":"J Neurol Sci"},{"issue":"2","key":"571_CR25","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s11136-013-0487-5","volume":"23","author":"WH Chen","year":"2014","unstructured":"Chen WH, Lenderking W, Jin Y, Wyrwich KW, Gelhorn H, Revicki DA. Is Rasch model analysis applicable in small sample size pilot studies for assessing item characteristics? An example using PROMIS pain behavior item bank data. Qual Life Res. 2014;23(2):485\u201393.","journal-title":"Qual Life Res"},{"issue":"7","key":"571_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201004","volume":"13","author":"A Chabanon","year":"2018","unstructured":"Chabanon A, Seferian AM, Daron A, P\u00e9r\u00e9on Y, Cances C, Vuillerot C, et al. Prospective and longitudinal natural history study of patients with Type 2 and 3 spinal muscular atrophy: baseline data NatHis-SMA study. PLoS ONE. 2018;13(7): e0201004.","journal-title":"PLoS ONE"},{"issue":"6","key":"571_CR27","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/0021-9681(87)90027-0","volume":"40","author":"AR Feinstein","year":"1987","unstructured":"Feinstein AR. Clinimetric perspectives. J Chron Dis. 1987;40(6):635\u201340.","journal-title":"J Chron Dis"},{"issue":"1","key":"571_CR28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1742-1241.2011.02825.x","volume":"66","author":"GA Fava","year":"2012","unstructured":"Fava GA, Tomba E, Sonino N. Clinimetrics: the science of clinical measurements. Int J Clin Pract. 2012;66(1):11\u20135.","journal-title":"Int J Clin Pract"},{"issue":"8","key":"571_CR29","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.jclinepi.2004.12.006","volume":"58","author":"GA Fava","year":"2005","unstructured":"Fava GA, Belaise C. A discussion on the role of clinimetrics and the misleading effects of psychometric theory. J Clin Epidemiol. 2005;58(8):753\u20136.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"571_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0172346","volume":"12","author":"D Ramsey","year":"2017","unstructured":"Ramsey D, Scoto M, Mayhew A, Main M, Mazzone ES, Montes J, et al. Revised Hammersmith Scale for spinal muscular atrophy: a SMA specific clinical outcome assessment tool. PLoS ONE. 2017;12(2): e0172346.","journal-title":"PLoS ONE"},{"issue":"4","key":"571_CR31","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.nmd.2014.01.003","volume":"24","author":"E Mazzone","year":"2014","unstructured":"Mazzone E, De Sanctis R, Fanelli L, Bianco F, Main M, van den Hauwe M, et al. Hammersmith functional motor scale and motor function measure-20 in non ambulant SMA patients. Neuromuscular Disord NMD. 2014;24(4):347\u201352.","journal-title":"Neuromuscular Disord NMD"},{"issue":"1","key":"571_CR32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12883-017-0790-9","volume":"17","author":"MC Pera","year":"2017","unstructured":"Pera MC, Coratti G, Forcina N, Mazzone ES, Scoto M, Montes J, et al. Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy. BMC Neurol. 2017;17(1):39.","journal-title":"BMC Neurol"},{"issue":"14","key":"571_CR33","doi-asserted-by":"publisher","first-page":"e1988","DOI":"10.1212\/WNL.0000000000010540","volume":"95","author":"CA Wijngaarde","year":"2020","unstructured":"Wijngaarde CA, Stam M, Otto LAM, Bartels B, Asselman FL, van Eijk RPA, et al. Muscle strength and motor function in adolescents and adults with spinal muscular atrophy. Neurology. 2020;95(14):e1988\u201398.","journal-title":"Neurology"},{"issue":"1","key":"571_CR34","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s13311-016-0472-0","volume":"14","author":"JM Shefner","year":"2017","unstructured":"Shefner JM. Strength testing in motor neuron diseases. Neurotherapeutics. 2017;14(1):154\u201360.","journal-title":"Neurotherapeutics"},{"key":"571_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.nrleng.2022.05.001","author":"P Lizandra Cort\u00e9s","year":"2022","unstructured":"Lizandra Cort\u00e9s P, Poveda Verd\u00fa D, Albert F\u00e9rriz A, \u00d1ungo-Garz\u00f3n NC, Domine MC, Sevilla-Mantec\u00f3n T, et al. Validation of Neuromyotype: a smart keyboard for the evaluation of spinal muscular atrophy patients. Neurologia. 2022. https:\/\/doi.org\/10.1016\/j.nrleng.2022.05.001.","journal-title":"Neurologia"},{"issue":"3","key":"571_CR36","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/mus.27785","volume":"67","author":"R Sadjadi","year":"2023","unstructured":"Sadjadi R, Kelly K, Glanzman AM, Montes J, Linsenmayer M, Tellez M, et al. Psychometric evaluation of modified spinal muscular atrophy functional rating scale (SMAFRS) in adult patients using Rasch analysis. Muscle Nerve. 2023;67(3):239\u201343.","journal-title":"Muscle Nerve"},{"issue":"3","key":"571_CR37","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/pri.221","volume":"6","author":"B Steffensen","year":"2001","unstructured":"Steffensen B, Hyde S, Lyager S, Mattsson E. Validity of the EK scale: a functional assessment of non-ambulatory individuals with Duchenne muscular dystrophy or spinal muscular atrophy. Physiother Res Int. 2001;6(3):119\u201334.","journal-title":"Physiother Res Int"},{"issue":"3","key":"571_CR38","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/mus.23937","volume":"49","author":"SJ Cano","year":"2014","unstructured":"Cano SJ, Mayhew A, Glanzman AM, Krosschell KJ, Swoboda KJ, Main M, et al. Rasch analysis of clinical outcome measures in spinal muscular atrophy. Muscle Nerve. 2014;49(3):422\u201330.","journal-title":"Muscle Nerve"},{"issue":"1","key":"571_CR39","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s40120-022-00411-2","volume":"12","author":"JF V\u00e1zquez-Costa","year":"2023","unstructured":"V\u00e1zquez-Costa JF, Branas-Pampill\u00f3n M, Medina-Cantillo J, Povedano M, Pitarch-Castellano I, L\u00f3pez-Lobato M, et al. Validation of a set of instruments to assess patient- and caregiver-oriented measurements in spinal muscular atrophy: results of the SMA-TOOL study. Neurol Ther. 2023;12(1):89\u2013105.","journal-title":"Neurol Ther"},{"key":"571_CR40","unstructured":"CHMP. Qualification opinion for Stride velocity 95th centile as primary endopoint in studies in ambulatory Duchenne Muscular Dystrophy in studies. 2023."},{"issue":"1","key":"571_CR41","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13023-020-01367-y","volume":"15","author":"CA Wijngaarde","year":"2020","unstructured":"Wijngaarde CA, Veldhoen ES, van Eijk RPA, Stam M, Otto LAM, Asselman FL, et al. Natural history of lung function in spinal muscular atrophy. Orphanet J Rare Dis. 2020;15(1):88.","journal-title":"Orphanet J Rare Dis"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00571-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-023-00571-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00571-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T14:13:06Z","timestamp":1705155186000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-023-00571-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,5]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["571"],"URL":"https:\/\/doi.org\/10.1007\/s40120-023-00571-9","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,5]]},"assertion":[{"value":"23 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr V\u00e1zquez-Costa is funded by grants from CUIDAME (Grant\/Award Number: PIC188-18), the Instituto de Salud Carlos III (JR19\/00030) and Generalitat Valenciana (Grant\/Award Number: EMERGENTES\/2021\/055) and received personal fees from Biogen and Roche outside the submitted work. Dr. M\u00f3nica Povedano received personal fees from Biogen, Ferrer, Grifols, Italfarmaco and Roche outside the submitted work. Sof\u00eda Garc\u00eda, Rosana Cabello and \u00c1ngeles Terrancle are employees of Roche Farma Spain. Pablo Rebollo is an employee of IQVIA Spain. Dr Mercedes Mart\u00ednez has received payment for presentations, training courses and advisory boards from Biogen, Roche and Novartis. Dra. Mar\u00eda Grazia Cattinari declares having attended medical congresses funded by Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"SMA-Life study is conducted in accordance with the Good Clinical Practice Guidelines of the International Conference on Harmonisation and with the ethical principles of the Declaration of Helsinki. The study was approved by the institutional review board of the Hospital Universitari de Bellvitge (Barcelona, Spain; reference code: PR264\/20). Written informed consent is obtained from all subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}